Annual report [Section 13 and 15(d), not S-K Item 405]

Asset Acquisition - Narrative (Details)

v3.25.1
Asset Acquisition - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Aug. 13, 2024
Mar. 28, 2024
Mar. 27, 2024
Oct. 31, 2024
Apr. 30, 2024
Dec. 31, 2024
Common stock            
Asset Acquisition [Line Items]            
Conversion of stock, issuance (in shares) 6,585,314          
Almata Transaction And March 2024 Financing            
Asset Acquisition [Line Items]            
Shares issuable in common stock (in shares)           349
Series C Preferred Stock | Almata Transaction And March 2024 Financing            
Asset Acquisition [Line Items]            
Shares issuable in common stock (in shares)     2,412      
Shares converted (in shares)     2,063      
AlmataBio Transaction            
Asset Acquisition [Line Items]            
Common stock shares issued (in shares)     171,605      
Shares issuable in common stock (in shares)     2,412      
Cash payments to acquire assets   $ 7,500     $ 7,500 $ 7,500
AlmataBio Transaction | Milestone One            
Asset Acquisition [Line Items]            
Contingent consideration   5,000        
Payments to acquire productive assets       $ 5,000    
AlmataBio Transaction | Milestone Two            
Asset Acquisition [Line Items]            
Contingent consideration   $ 15,000        
AlmataBio Transaction | Common stock            
Asset Acquisition [Line Items]            
Conversion of stock, issuance (in shares)     2,062,930